Skip to main content

Advertisement

SpringerLink
Log in

Generation of Plasmid DNA Expressing Species-Specific Horse VEGF164 and FGF2 Factors for Gene Therapy

  • Published:
BioNanoScience Aims and scope Submit manuscript

Abstract

In this study, we have generated a dual expression cassette plasmid DNA (pDNA) construct containing the species-specific horse (Equus caballus) codon optimized sequence encoding potent pro-angiogenic vascular endothelial growth factor (VEGF164) and basic fibroblast growth factor (FGF2) under eukaryotic promoters (EF-1α and CMV promoters, respectively). We have demonstrated effective and simultaneous recombinant proteins expression in vitro. Resulting pDNA is suitable for potential gene therapy applications in horses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rizvanov, A. A, Guseva, D. S., Salafutdinov, I. I., Kudryashova, N. V, Bashirov, F. V, Kiyasov, A. P., … Islamov, R. R. (2011). Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Experimental Biology and Medicine (Maywood, N.J.)., 236(1), 91–98. doi:10.1258/ebm.2010.010172.

  2. Adas, G., Percem, A., Adas, M., Kemik, O., Arikan, S., Ustek, D., … Karatepe, O. (2011). VEGF-A and FGF gene therapy accelerate healing of ischemic colonic anastomoses (experimental study). International Journal of Surgery, 9(6), 467–471. doi:10.1016/j.ijsu.2011.05.002.

  3. Zor, F., Deveci, M., Kilic, A., Ozdag, M. F., Kurt, B., Sengezer, M., et al. (2014). Effect of VEGF gene therapy and hyaluronic acid film sheath on peripheral nerve regeneration. Microsurgery, 34(3), 209–216. doi:10.1002/micr.22196.

    Article  Google Scholar 

  4. Byrne, A. M., Bouchier-Hayes, D. J., Harmey, J. H. (2005). Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). Journal of Cellular and Molecular Medicine, 9(4), 777–794.

    Article  Google Scholar 

  5. Lee, T. J., Jang, J., Kang, S., Jin, M., Shin, H., Kim, D. W., et al. (2013). Enhancement of osteogenic and chondrogenic differentiation of human embryonic stem cells by mesodermal lineage induction with BMP-4 and FGF2 treatment. Biochemical and Biophysical Research Communications, 430(2), 793–797. doi:10.1016/j.bbrc.2012.11.067.

    Article  Google Scholar 

  6. Kühn, M. C., Willenberg, H. S., Schott, M., Papewalis, C., Stumpf, U., Flohé, S., … Schinner, S. (2012). Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation. Molecular and Cellular Endocrinology, 349(2), 180–188. doi:10.1016/j.mce.2011.10.018

  7. Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Food and Drug Administration (FDA). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091968.pdf.

  8. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for human gene therapy investigational new drug applications (INDs). Food and Drug Administration (FDA). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm092705.pdf.

  9. Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003942.pdf.

  10. Guideline on follow-up of patients administered with gene therapy medicinal products. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500013424.pdf.

  11. Reflection paper on design modifications of gene therapy medicinal products during development. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500122743.pdf.

  12. pBudCE4.1 Mammalian expression vector. ThermoFisher Scientific. https://tools.thermofisher.com/content/sfs/vectors/pbudce4_1_map.pdf.

Download references

Acknowledgments

This work is performed according to the Russian Government Program of Competitive Growth of Kazan Federal University and subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities. Some of the experiments were conducted using the equipment of Interdisciplinary center for collective use of Kazan Federal University supported by the Ministry of Education of Russia (ID RFMEFI59414X0003), Interdisciplinary Center for Analytical Microscopy, and Pharmaceutical Research and Education Center, Kazan (Volga Region) Federal University, Kazan, Russia.

Author information

Authors and Affiliations

  1. Kazan Federal University, Kazan, Russia

    Y. A. Litvin, E. Yu Zakirova, M. N. Zhuravleva & A. A. Rizvanov

Authors
  1. Y. A. Litvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Yu Zakirova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. N. Zhuravleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. Rizvanov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Rizvanov.

Ethics declarations

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Litvin, Y.A., Zakirova, E.Y., Zhuravleva, M.N. et al. Generation of Plasmid DNA Expressing Species-Specific Horse VEGF164 and FGF2 Factors for Gene Therapy. BioNanoSci. 6, 550–553 (2016). https://doi.org/10.1007/s12668-016-0273-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12668-016-0273-2

Keywords

Search

Navigation